A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Explore this paper's citation graph
Summary
Ruxolitinib provided significant clinical benefits in patients with myelofibrosis by reducing spleen size, improving debilitating myelofibrosis-related symptoms, and improving overall survival.
- Type
- article
- Published
- 2012-03-01
- Cited by
- 1,929
- References
- 17
- Access
- Open access
- OpenAlex
- https://openalex.org/W2121743767
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2868020
Keywords
Ruxolitinib, Myelofibrosis, Janus kinase inhibitor, Placebo, Medicine
References
- Evaluating the Serial Use of the Myelofibrosis Symptom Assessment Form for Measuring Symptomatic Improvement
- Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
- Estimation of spleen volume using MR imaging and a random marking technique
- JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
- Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus
- Molecular aspects of myeloproliferative neoplasms
- Regulation of myelopoiesis through syntenin-mediated modulation of IL-5 receptor output.
- Splenic volume measurements on computed tomography utilizing automatically contouring software and its relationship with age, gender, and anthropometric parameters.
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
- Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
- International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
- Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial.
Cited by
- Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
- Surprising results of a supportive integrated therapy in myelofibrosis.
- Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities
- Emerging drugs for the treatment of myelofibrosis
- Current Challenges in Stem Cell Transplantation in Myelofibrosis
- B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6
- Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
- Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches
- Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
- Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial
- Efficacy and safety of ruxolitinib in intermediate‐1 IPSS risk myelofibrosis patients: Results from an independent study
- The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects
- Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
- Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation.
- The anti-cancer activity of a first-in-class small molecule targeting PCNA
- Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.
- Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis
- JAK3/STAT5 signaling cascade represents a therapeutic target to treat select hematologic malignancies
Related papers
- Janus kinase inhibitors in myeloproliferative neoplasms: Clinical applications
- Janus activated kinase inhibition in myelofibrosis.
- Population Pharmacokinetic Analysis of Orally‐Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post‐Polycythemia Vera Myelofibrosis (PPV‐MF) or Post‐Essential Thrombocythemia Myelofibrosis (PET MF)
- Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis
- Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis
- Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response
- Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians
- Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis
- The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.